Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Analysts see Doximity stock outperforming on earnings, shorts covering

Published 11/11/2022, 07:37 AM
Updated 11/11/2022, 07:58 AM
© Reuters.  Analyst sees Doximity (DOCS) stock outperforming on earnings, shorts covering

© Reuters. Analyst sees Doximity (DOCS) stock outperforming on earnings, shorts covering

By Senad Karaahmetovic

Shares of Doximity (NYSE:DOCS) are up over 18% in pre-open trading after the company reported better-than-expected results for its fiscal second quarter.

Doximity reported EPS of $0.17 on revenue of $102.2 million, ahead of the consensus that called for EPS of $0.15 on sales of $100.29 million. The company generated $46 million in adjusted EBITDA.

For this quarter, Doximity said it expects to generate $111.2 million (the midpoint) in revenue, lower than the $114.88 million consensus. The adjusted EBITDA is seen at $46.7 million (the midpoint), again missing the $52.6 million consensus. The company reaffirmed its full-year forecast for revenue and adjusted EBITDA.

DOCS stock has also been boosted by the new buyback plan for up to $70 million of the company’s Class common stock.

Evercore ISI analysts said the FQ2 performance is "a sigh of relief." The analysts raised the price target to $32 per share from $28 to reflect a "reaffirmed outlook and improving investor comfort around inflation."

However, they remain In-line rated on DOCS stock as is "still at risk of facing pharma budget headwinds going into the back half of FY23 despite its stronger than guided performance in 2Q23 (will keep eye out in 2H23)."

Wells Fargo analysts reiterated an Overweight rating and raised the price target to $44 per share from $38. The analysts are especially positive about the updates during the earnings call, including the improved ROI stats.

"We believe these metrics will improve DOCS' growth prospects and business defensibility, as a higher ROI helps justify price increases for renewed contracts, helps capture new business and incremental ad budget spend, take share from competitors, and ideally place DOCS last in line if/when clients seek places to cut spend," the analysts wrote in a note.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.